Koji Hasegawa
Overview
Explore the profile of Koji Hasegawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
330
Citations
4690
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rosano G, Ono K, Imbalzano E, Hasegawa K
Eur Heart J Cardiovasc Pharmacother
. 2025 Jan;
11(1):20-21.
PMID: 39776152
No abstract available.
2.
Masunaga N, Ishii M, Oka K, Okamoto K, Yoshida Y, Minami K, et al.
Circ J
. 2024 Oct;
89(2):174-183.
PMID: 39477486
Background: Anticoagulation therapy for atrial fibrillation (AF) has undergone major changes following the introduction of direct oral anticoagulants (DOAC) in 2011. However, the transition of anticoagulation therapy for AF patients...
3.
Komiyama M, Hasegawa K, Rosano G
Eur Heart J Cardiovasc Pharmacother
. 2024 Oct;
11(1):3-4.
PMID: 39474899
No abstract available.
4.
Hamatani Y, Iguchi M, Kato T, Inuzuka Y, Tamaki Y, Ozasa N, et al.
ESC Heart Fail
. 2024 Sep;
12(1):389-400.
PMID: 39305136
Aims: Atrial fibrillation (AF) and heart failure (HF) with preserved ejection fraction (HFpEF) are interlinked and frequently coexisting conditions. To date, patients with AF and HFpEF have limited evidence guiding...
5.
Komiyama M, Iguchi M, Wada H, Ikeda T, Dan G, Hasegawa K
Eur Cardiol
. 2024 Jul;
19:e10.
PMID: 39081482
Factor XIa (FXIa) may be involved in thrombus formation, but only to a lesser extent involved in haemostasis. Several novel FXIa inhibitors are under investigation, and Phase II trials demonstrated...
6.
Toda Kato E, Hasegawa K, Ono K
Eur Heart J Cardiovasc Pharmacother
. 2024 Jul;
10(6):486-487.
PMID: 38986503
No abstract available.
7.
Dalmau R, Alanazi A, Arora M, Banerjee A, Bianco E, Gaalema D, et al.
Glob Heart
. 2024 Jul;
19(1):55.
PMID: 38973985
The Coronavirus Disease 2019, commonly referred to as COVID-19, is responsible for one of the deadliest pandemics in human history. The direct, indirect and lasting repercussions of the COVID-19 pandemic...
8.
Esato M, Fujino A, Hamatani Y, Yoshizawa T, Ide Y, Ishii M, et al.
Am J Cardiol
. 2024 Jun;
227():37-47.
PMID: 38936788
Some patients with atrial fibrillation (AF), albeit less frequently, may regress from sustained to paroxysmal type. We sought to investigate how the regression of AF is associated with outcomes. Among...
9.
Kishimoto A, Komiyama M, Wada H, Satoh-Asahara N, Yamakage H, Ajiro Y, et al.
J Health Popul Nutr
. 2024 Jun;
43(1):93.
PMID: 38915116
Introduction: Even after the peak of the COVID-19 pandemic, the number of mild cases remains high, requiring continuous control. Curcumin, owing to its anti-inflammatory properties, can suppress vital proliferation and...
10.
Sun Y, Hasegawa K, Drexel H
Eur Heart J Cardiovasc Pharmacother
. 2024 May;
10(4):278.
PMID: 38697932
No abstract available.